期刊
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
卷 16, 期 5, 页码 E154-E159出版社
WILEY
DOI: 10.1111/ajco.13365
关键词
adverse effects; cancer; checkpoint inhibitor; combination immunotherapy; T cell
类别
资金
- Beijing Municipal Science and Technology Commission [Z181100001718104]
- Science Foundation of Peking University Cancer Hospital [18-02, 2020-4]
- BeijingMunicipal Administration of Hospitals IncubatingProgram [PX2020045]
With the development of cancer immunotherapy, the combination strategy is becoming prevalent. Multiple relevant clinical trials are ongoing in this field. However, immune-related adverse events (irAEs) occurred more frequently, showing a different pattern from single-agent therapy. It is necessary for clinicians to learn about the characteristics of AEs from combination immunotherapy, and master the skills to deal with them. In this article, we reviewed presently published data about AEs from combination immunotherapy of cancers. We believe a full-scale view about this new treatment strategy will facilitate oncologists to better understand tumor immune response. With cutting edge knowledge, an experienced team can minimize these AEs and help patients to achieve high-quality long-term survival.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据